IN2014CN00414A - - Google Patents
Info
- Publication number
- IN2014CN00414A IN2014CN00414A IN414CHN2014A IN2014CN00414A IN 2014CN00414 A IN2014CN00414 A IN 2014CN00414A IN 414CHN2014 A IN414CHN2014 A IN 414CHN2014A IN 2014CN00414 A IN2014CN00414 A IN 2014CN00414A
- Authority
- IN
- India
- Prior art keywords
- amino acid
- acid sequences
- polypeptides
- proteins
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161500464P | 2011-06-23 | 2011-06-23 | |
PCT/EP2012/061304 WO2012175400A1 (fr) | 2011-06-23 | 2012-06-14 | Protéines se liant à la sérumalbumine |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN00414A true IN2014CN00414A (fr) | 2015-04-03 |
Family
ID=46298413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN414CHN2014 IN2014CN00414A (fr) | 2011-06-23 | 2012-06-14 |
Country Status (17)
Country | Link |
---|---|
US (2) | US9573992B2 (fr) |
EP (3) | EP3466972A1 (fr) |
JP (3) | JP6324887B2 (fr) |
CN (2) | CN106046168A (fr) |
AU (1) | AU2012271974B2 (fr) |
CA (1) | CA2839779C (fr) |
CY (1) | CY1122691T1 (fr) |
DK (1) | DK2723771T3 (fr) |
ES (1) | ES2759936T3 (fr) |
HR (2) | HRP20170535T4 (fr) |
HU (1) | HUE047238T2 (fr) |
IN (1) | IN2014CN00414A (fr) |
LT (1) | LT2723771T (fr) |
PL (1) | PL2723771T3 (fr) |
PT (1) | PT2723771T (fr) |
SI (1) | SI2723771T1 (fr) |
WO (1) | WO2012175400A1 (fr) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2621953B1 (fr) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Matières biologiques associées à c-met |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
IL293155A (en) | 2011-06-23 | 2022-07-01 | Ablynx Nv | Techniques for predicting, detecting, and reducing A-specific protein interference in assays involving single immunoglobulin variable domains |
LT2723771T (lt) * | 2011-06-23 | 2019-12-10 | Ablynx Nv | Serumo albuminą surišantys baltymai |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
WO2013045707A2 (fr) * | 2011-09-30 | 2013-04-04 | Ablynx Nv | Substances biologiques liées à c-met |
WO2014087010A1 (fr) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | Polypeptides améliorés dirigés contre ige |
SG10201805288QA (en) | 2014-05-16 | 2018-07-30 | Ablynx Nv | Improved immunoglobulin variable domains |
EP3143403B1 (fr) | 2014-05-16 | 2021-10-27 | Ablynx N.V. | Méthodes pour détecter et/ou mesurer des anticorps anti-médicaments, en particulier des anticorps anti-médicaments dus au traitement |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
PL3233910T3 (pl) | 2014-12-19 | 2020-06-01 | Ablynx N.V. | Dimery nanociał połączone cysteiną |
WO2016120843A1 (fr) | 2015-01-29 | 2016-08-04 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Molécules d'anticorps et systèmes d'administration peptidiques destinés à être utilisés dans la maladie d'alzheimer et autres troubles apparentés |
EP3297672B1 (fr) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Protéines trispécifiques de liaison et méthodes d'utilisation |
NO2768984T3 (fr) | 2015-11-12 | 2018-06-09 | ||
AU2016351710B2 (en) | 2015-11-13 | 2023-08-03 | Ablynx Nv | Improved serum albumin-binding immunoglobulin variable domains |
PE20181532A1 (es) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Enlazadores de pd1 y/o lag3 |
US11332519B2 (en) * | 2015-11-18 | 2022-05-17 | Ablynx N.V. | Serum albumin binders |
JP6768800B2 (ja) | 2015-11-18 | 2020-10-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Ctla4結合性物質 |
CA3003777A1 (fr) | 2015-11-18 | 2017-05-26 | Merck Sharp & Dohme Corp. | Liants pd1/ctla4 |
CA3006398A1 (fr) * | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibant le ligand cd40l |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
MX2018014228A (es) | 2016-05-20 | 2019-08-12 | Harpoon Therapeutics Inc | Proteina de union de albumina sérica de dominio unico. |
BR112018076569A2 (pt) | 2016-06-23 | 2019-04-02 | Ablynx Nv | ensaios farmacocinéticos melhorados para domínios variáveis simples de imunoglobulina |
MX2019005696A (es) | 2016-11-16 | 2019-08-14 | Ablynx Nv | Polipeptidos de reclutamiento de celulas t capaces de unir cd123 y tcr alfa/beta. |
US11414480B2 (en) * | 2016-12-07 | 2022-08-16 | Ablynx N.V. | Serum albumin binding immunoglobulin single variable domains |
CN107674122A (zh) * | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | 一种识别人血清白蛋白的单域抗体 |
SG11201906264YA (en) | 2017-01-17 | 2019-08-27 | Ablynx Nv | Improved serum albumin binders |
KR20230165374A (ko) * | 2017-01-17 | 2023-12-05 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
CN110546506B (zh) | 2017-03-31 | 2023-04-04 | 埃博灵克斯股份有限公司 | 改进的免疫原性测定法 |
US10543271B2 (en) | 2017-05-12 | 2020-01-28 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
CA3078799A1 (fr) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Proteines de liaison a l'antigene de maturation de cellules b |
WO2019162521A1 (fr) * | 2018-02-26 | 2019-08-29 | Ablynx Nv | Séquences nucléotidiques améliorées codant des lieurs peptidiques |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
CN110964107B (zh) * | 2018-09-30 | 2022-08-09 | 苏州康宁杰瑞生物科技有限公司 | Met结合分子、其组合和用途 |
CN111138536B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 抗人血清白蛋白单域抗体的制备及其应用 |
CN111138537B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 一种抗人血清白蛋白抗体片段、制备方法和应用 |
BR112022010231A2 (pt) | 2019-12-06 | 2022-09-06 | Ablynx Nv | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a tnfalfa e ox40l |
CA3163877A1 (fr) | 2019-12-06 | 2021-06-10 | Ablynx Nv | Polypeptides comprenant des domaines variables uniques d'immunoglobuline ciblant tnf.alpha. et il-23 |
JP2023504914A (ja) | 2019-12-09 | 2023-02-07 | アブリンクス・エヌ・フェー | Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド |
CN110988361B (zh) * | 2019-12-13 | 2020-09-18 | 山东民康生物科技有限公司 | 人血清白蛋白去除试剂盒 |
AU2021224851A1 (en) | 2020-02-21 | 2022-09-15 | Harpoon Therapeutics, Inc. | FLT3 binding proteins and methods of use |
IL296767A (en) | 2020-03-30 | 2022-11-01 | Ablynx Nv | A method for the production and purification of single variable multivalent immunoglobulin sites |
JP2023544124A (ja) | 2020-09-25 | 2023-10-20 | アブリンクス エン.ヴェー. | Il-13およびox40lを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド |
CN112142846B (zh) * | 2020-10-10 | 2022-07-08 | 西北大学 | Aox特异性抗体组合及其制备方法和用途 |
EP4237438A1 (fr) | 2020-10-27 | 2023-09-06 | Beijing QL Biopharmaceutical Co., Ltd. | Protéines de fusion de gdf15 et leur utilisation |
IL303783A (en) | 2020-12-18 | 2023-08-01 | Sanofi Sa | Polypeptides comprising single immunoglobulin variable sites targeting GLYPICAN-3 and the T-cell receptor |
WO2022129572A1 (fr) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprenant des domaines variables uniques d'immunoglobuline ciblant il-6 et tnf-alpha |
CA3203141A1 (fr) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides de recrutement de lymphocytes t bases sur la reactivite tcr alpha/beta |
CA3224743A1 (fr) * | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptides de fusion pour troubles metaboliques |
WO2023088295A1 (fr) * | 2021-11-17 | 2023-05-25 | 江苏先声药业有限公司 | Anticorps multi-spécifique et utilisation pharmaceutique associée |
WO2023111266A1 (fr) | 2021-12-17 | 2023-06-22 | Ablynx Nv | POLYPEPTIDES COMPRENANT DES DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT TCRαβ, CD33 ET CD123 |
CN118139892A (zh) * | 2022-01-14 | 2024-06-04 | 浙江道尔生物科技有限公司 | 一种三靶点抗肿瘤药物、其制备方法及其应用 |
US20240109965A1 (en) | 2022-06-14 | 2024-04-04 | Ablynx N.V. | Immunoglobulin single variable domains targeting t cell receptor |
WO2023242371A1 (fr) | 2022-06-15 | 2023-12-21 | argenx BV | Molécules de liaison hsa dépendantes du ph et procédés d'utilisation |
US20240132624A1 (en) | 2022-07-27 | 2024-04-25 | Ablynx N.V. | Polypeptides binding to a specific epitope of the neonatal fc receptor |
WO2024084203A1 (fr) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Anticorps à domaine unique se liant à l'albumine |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
DE69334305D1 (de) | 1992-08-21 | 2010-01-28 | Univ Bruxelles | Immunoglobuline ohne leichte Ketten |
EP0698097B1 (fr) | 1993-04-29 | 2001-08-16 | Unilever N.V. | Production d'anticorps ou de fragments fonctionnalises d'anticorps, derives des immunoglobulines a chaine lourde de camelidae |
EP0739981A1 (fr) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire |
DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
NZ540196A (en) | 2002-11-08 | 2008-09-26 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
KR20050092029A (ko) | 2003-01-10 | 2005-09-16 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자(vWF) 또는 콜라겐에 대한낙타과로부터의 재조합 VHH 단일 도메인 항체 |
DE602005020799D1 (de) | 2004-08-05 | 2010-06-02 | Genentech Inc | Humanisierte anti-cmet-antagonisten |
US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
WO2006129843A2 (fr) | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Molecule de capture de substance cible |
WO2006129828A2 (fr) | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Molecule de capture de substance active |
EP1976991A1 (fr) | 2006-01-24 | 2008-10-08 | Domantis Limited | Protéines de fusion contenant des jonctions naturelles |
TW200815470A (en) * | 2006-03-30 | 2008-04-01 | Novartis Ag | Compositions and methods of use for antibodies of c-Met |
US7741273B2 (en) | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
KR20090039739A (ko) | 2006-08-03 | 2009-04-22 | 아스트라제네카 아베 | αVβ6에 대해 작용하는 항체 및 그의 용도 |
US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
WO2008028977A2 (fr) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Protéines à demi-vie longue se liant à l'albumine sérique |
EP2086998B1 (fr) * | 2006-10-11 | 2011-12-07 | Ablynx N.V. | Sequences d'acides amines se liant a des proteines seriques essentiellement independamment du ph, composes comprenant celles et utilisations correspondantes |
WO2009138519A1 (fr) | 2008-05-16 | 2009-11-19 | Ablynx Nv | Séquences d'acides aminés dirigées contre cxcr4 et autres gpcr et composés renfermant ces dernières |
GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
KR20120125601A (ko) | 2007-05-24 | 2012-11-16 | 아블린쓰 엔.브이. | Rank-l에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드 |
EP2014681A1 (fr) * | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes |
WO2009032949A2 (fr) | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | Anticorps d'antigène de cellule souche anti-prostate (psca) à haute affinité pour un ciblage et une détection de cancer |
CA2704134A1 (fr) | 2007-09-24 | 2009-04-02 | Vanderbilt University | Anticorps monoclonaux au virus respiratoire syncytial et leurs utilisations |
EP2650311A3 (fr) | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Séquences d'acides aminés dirigées contre des cytokines hétérodimériques et/ou leurs récepteurs et polypeptides les comprenant |
WO2009097128A1 (fr) | 2008-01-29 | 2009-08-06 | Ludwig Institute For Cancer Research Ltd. | Épitope napi2b (slc34a2) de transport à travers les membranes pour une thérapie par anticorps, anticorps dirigés contre celui-ci, et cible pour une thérapie du cancer |
SI2285408T1 (sl) | 2008-06-05 | 2019-02-28 | Ablynx N.V. | Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni |
EP2143735A1 (fr) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Domaines variables d'anticorps de camélidé à chaîne lourde dirigés contre les protéines acides fibrillaires gliales |
US20110200525A1 (en) | 2008-10-09 | 2011-08-18 | Patz Jr Edward F | Vhh antibody fragments for use in the detection and treatment of cancer |
AU2009314311B2 (en) | 2008-10-29 | 2013-01-10 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
EA021146B1 (ru) * | 2009-03-27 | 2015-04-30 | Глаксо Груп Лимитед | Продукты слияния и конъюгаты лекарственных средств |
US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
SI2513147T1 (sl) | 2009-12-18 | 2016-11-30 | Sanofi | Nova protitelesa antagonisti in njihovi delci Fab proti GPVI in njihova uporaba |
CA2788275A1 (fr) | 2010-03-03 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Polypeptides de liaison beta-amyloides biparatopiques |
EA201201273A1 (ru) | 2010-03-10 | 2013-02-28 | Генмаб А/С | Моноклональные антитела к с-мет |
EP2621953B1 (fr) * | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Matières biologiques associées à c-met |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
LT2723771T (lt) * | 2011-06-23 | 2019-12-10 | Ablynx Nv | Serumo albuminą surišantys baltymai |
US20150344568A1 (en) | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
IL293155A (en) | 2011-06-23 | 2022-07-01 | Ablynx Nv | Techniques for predicting, detecting, and reducing A-specific protein interference in assays involving single immunoglobulin variable domains |
PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
-
2012
- 2012-06-14 LT LT12727658T patent/LT2723771T/lt unknown
- 2012-06-14 CA CA2839779A patent/CA2839779C/fr active Active
- 2012-06-14 SI SI201231696T patent/SI2723771T1/sl unknown
- 2012-06-14 DK DK12727658T patent/DK2723771T3/da active
- 2012-06-14 CN CN201610392570.9A patent/CN106046168A/zh active Pending
- 2012-06-14 US US14/128,719 patent/US9573992B2/en active Active
- 2012-06-14 EP EP18205150.8A patent/EP3466972A1/fr active Pending
- 2012-06-14 JP JP2014516279A patent/JP6324887B2/ja active Active
- 2012-06-14 CN CN201280030647.8A patent/CN103619878B/zh active Active
- 2012-06-14 PT PT127276582T patent/PT2723771T/pt unknown
- 2012-06-14 EP EP12727658.2A patent/EP2723771B1/fr active Active
- 2012-06-14 HU HUE12727658A patent/HUE047238T2/hu unknown
- 2012-06-14 PL PL12727658T patent/PL2723771T3/pl unknown
- 2012-06-14 AU AU2012271974A patent/AU2012271974B2/en active Active
- 2012-06-14 EP EP23159592.7A patent/EP4218933A1/fr active Pending
- 2012-06-14 WO PCT/EP2012/061304 patent/WO2012175400A1/fr active Application Filing
- 2012-06-14 ES ES12727658T patent/ES2759936T3/es active Active
- 2012-06-14 IN IN414CHN2014 patent/IN2014CN00414A/en unknown
- 2012-06-25 HR HRP20170535TT patent/HRP20170535T4/hr unknown
-
2017
- 2017-01-03 US US15/397,313 patent/US20170210789A1/en not_active Abandoned
-
2018
- 2018-04-11 JP JP2018076201A patent/JP6843090B2/ja active Active
-
2019
- 2019-11-29 HR HRP20192160TT patent/HRP20192160T1/hr unknown
- 2019-12-10 CY CY20191101299T patent/CY1122691T1/el unknown
-
2021
- 2021-02-22 JP JP2021026177A patent/JP7304375B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
HRP20170535T4 (hr) | 2022-08-19 |
JP2014520129A (ja) | 2014-08-21 |
PL2723771T3 (pl) | 2020-04-30 |
AU2012271974A1 (en) | 2013-12-12 |
EP2723771B1 (fr) | 2019-09-11 |
CN106046168A (zh) | 2016-10-26 |
SI2723771T1 (sl) | 2019-12-31 |
JP2021088585A (ja) | 2021-06-10 |
HRP20170535T1 (hr) | 2017-06-16 |
EP2723771A1 (fr) | 2014-04-30 |
ES2759936T3 (es) | 2020-05-12 |
US20140228546A1 (en) | 2014-08-14 |
JP7304375B2 (ja) | 2023-07-06 |
PT2723771T (pt) | 2019-12-11 |
HUE047238T2 (hu) | 2020-04-28 |
EP3466972A1 (fr) | 2019-04-10 |
WO2012175400A1 (fr) | 2012-12-27 |
CY1122691T1 (el) | 2021-03-12 |
LT2723771T (lt) | 2019-12-10 |
JP2018127478A (ja) | 2018-08-16 |
AU2012271974B2 (en) | 2017-01-12 |
US9573992B2 (en) | 2017-02-21 |
CN103619878B (zh) | 2016-10-26 |
CN103619878A (zh) | 2014-03-05 |
HRP20192160T1 (hr) | 2020-02-21 |
DK2723771T3 (da) | 2019-12-02 |
CA2839779C (fr) | 2020-10-06 |
US20170210789A1 (en) | 2017-07-27 |
JP6324887B2 (ja) | 2018-05-16 |
CA2839779A1 (fr) | 2012-12-27 |
EP4218933A1 (fr) | 2023-08-02 |
JP6843090B2 (ja) | 2021-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN00414A (fr) | ||
WO2008028977A3 (fr) | Protéines à demi-vie longue se liant à l'albumine sérique | |
PH12019500596A1 (en) | Recombinant binding proteins and their use | |
IN2014CN00437A (fr) | ||
MX2013012844A (es) | Secuencias de aminoacidos dirigidas contra il-17a, il-17f y/o il-17a/f y polipeptidos que comprenden las mismas. | |
MY162737A (en) | 4-1bb binding molecules | |
CA2818990C (fr) | Proteines de repetition concues se liant a l'albumine serique | |
WO2013040093A3 (fr) | Compositions de peptide-2 de type glucagon et leurs procédés de fabrication et d'utilisation | |
AU2016240220B2 (en) | Designed ankyrin repeat domains with binding specificity for serum albumin | |
MX350962B (es) | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. | |
MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
MX2019013983A (es) | Composiciones de factor viii y metodos para hacerlas y usarlas. | |
WO2013184938A3 (fr) | Polypeptides de fusion comprenant des lieurs polypeptides à domaine mucin | |
WO2008043822A3 (fr) | Séquences d'acides aminés se liant de façon conditionnelle à une molécule désirée | |
DK1888641T3 (da) | Serumalbuminbindende proteiner | |
MX2014011459A (es) | Proteinas nutritivas cargadas y metodos. | |
EP2250278A4 (fr) | Procédés et compositions liés aux peptides et aux protéines avec des éléments c-terminaux en référence croisée aux applications connexes | |
WO2009147248A3 (fr) | Séquences d'acides aminés dirigées contre des protéines d'enveloppe d'un virus, et polypeptides comprenant ces séquences destinés au traitement de maladies virales | |
IN2014DN05756A (fr) | ||
PH12014501200A1 (en) | Bacteriophage gene 3 protein compositions and use as amyloid binding agents | |
MX2009004243A (es) | Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal. | |
MX2015000754A (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
WO2012091564A3 (fr) | Polypeptide de réticulation induisant l'apoptose | |
WO2019014360A8 (fr) | Polypeptides se liant au composant c5 du complément ou à l'albumine sérique et protéines de fusion de ceux-ci | |
MX2012004295A (es) | Composicion para el tratamiento de esclerosis multiple. |